What is a stock summary page? Click here for an overview.
Business Description
Guardant Health Inc
NAICS : 621511
SIC : 8071
ISIN : US40131M1099
Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | -0.09 | |||||
| Debt-to-Equity | -9.57 | |||||
| Debt-to-EBITDA | -3.43 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.05 | |||||
| Beneish M-Score | -2.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.7 | |||||
| 3-Year EBITDA Growth Rate | 3.6 | |||||
| 3-Year EPS without NRI Growth Rate | 6.8 | |||||
| 3-Year FCF Growth Rate | 7.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.35 | |||||
| 9-Day RSI | 65.97 | |||||
| 14-Day RSI | 60.9 | |||||
| 3-1 Month Momentum % | -1.59 | |||||
| 6-1 Month Momentum % | 126.52 | |||||
| 12-1 Month Momentum % | 170.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.68 | |||||
| Quick Ratio | 4.36 | |||||
| Cash Ratio | 3.72 | |||||
| Days Inventory | 84.46 | |||||
| Days Sales Outstanding | 45.86 | |||||
| Days Payable | 46.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.8 | |||||
| Shareholder Yield % | 0.32 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.79 | |||||
| Operating Margin % | -60.03 | |||||
| Net Margin % | -59.05 | |||||
| FCF Margin % | -37.2 | |||||
| ROE % | -8518.58 | |||||
| ROA % | -26.85 | |||||
| ROIC % | -84.13 | |||||
| 3-Year ROIIC % | 5.12 | |||||
| ROC (Joel Greenblatt) % | -137.35 | |||||
| ROCE % | -30.57 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.02 | |||||
| EV-to-EBIT | -14.68 | |||||
| EV-to-Forward-EBIT | -14.27 | |||||
| EV-to-EBITDA | -16.27 | |||||
| EV-to-Forward-EBITDA | -16.73 | |||||
| EV-to-Revenue | 8.59 | |||||
| EV-to-Forward-Revenue | 7.41 | |||||
| EV-to-FCF | -23.09 | |||||
| Price-to-GF-Value | 1.21 | |||||
| Earnings Yield (Greenblatt) % | -6.81 | |||||
| FCF Yield % | -4.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guardant Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 739.016 | ||
| EPS (TTM) ($) | -3.56 | ||
| Beta | 1.74 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 104.86 | ||
| 14-Day RSI | 60.9 | ||
| 14-Day ATR ($) | 2.970282 | ||
| 20-Day SMA ($) | 43.6265 | ||
| 12-1 Month Momentum % | 170.75 | ||
| 52-Week Range ($) | 16.77 - 50.89 | ||
| Shares Outstanding (Mil) | 123.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guardant Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guardant Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guardant Health Inc Frequently Asked Questions
What is Guardant Health Inc(GH)'s stock price today?
The current price of GH is $48.30. The 52 week high of GH is $50.89 and 52 week low is $16.77.
When is next earnings date of Guardant Health Inc(GH)?
The next earnings date of Guardant Health Inc(GH) is 2025-04-30.
Does Guardant Health Inc(GH) pay dividends? If so, how much?
Guardant Health Inc(GH) does not pay dividend.
Guru Commentaries on NAS:GH
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers